CA2204160A1 - Treatment of urogenital cancer with boron neutron capture therapy - Google Patents
Treatment of urogenital cancer with boron neutron capture therapyInfo
- Publication number
- CA2204160A1 CA2204160A1 CA002204160A CA2204160A CA2204160A1 CA 2204160 A1 CA2204160 A1 CA 2204160A1 CA 002204160 A CA002204160 A CA 002204160A CA 2204160 A CA2204160 A CA 2204160A CA 2204160 A1 CA2204160 A1 CA 2204160A1
- Authority
- CA
- Canada
- Prior art keywords
- carboran
- boron
- therapy
- urogenital
- carboranyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
- A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
Abstract
Methods and compositions for treating urogenital tumors, and in particular, cancer of the prostate, bladder, and kidney, with BCNT, are disclosed. Any boron-containing compound that is sufficiently lipophilic to pass through the appropriate urogenital membranes in a quantity high enough to achieve therapy on irradiation with low-energy neutrons can be used. Carboranyl-containing nucleosides and oligonucleotides are particularly suited for use in BNCT of urogenital tumors.
Preferred compounds include 5-carboranyl-2'-deoxyuridine (CDU) and 5-o-carboranyl-l-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)uracil (CFAU). Nucleosides and oligonucleotides bearing an -O-[(carboran-1-yl)alkyl]phosphate, S-[(carboran-1-yl)alkyl]phosphorothioate, or Se-[(carboran-1-yl)alkyl]phosphoroselenoate in place of the (carboran-1-yl)phosphonate moiety can be used. Oligonucleotides of specific gene sequences that include one or more 3', 5'-linking-(carboran-1-yl)phosphonate moieties can also be used in antisense therapy in the selective modification of gene expression. Compounds can be used in urogenital BNCT therapy that contain boron clusters as a means to enhance lipophilicity wherein the boron is not enriched in 10B, but instead, in the 11B isotope. The therapy is accomplished by administering the boron-containing compound by any appropriate route, including by intravenous injection, oral delivery or by catheter or other direct means, in such a manner that the compound accumulates in the target tumor. After desired accumulation of the compound in the tumor, the site is irradiated with an effective amount of low energy neutrons.
Preferred compounds include 5-carboranyl-2'-deoxyuridine (CDU) and 5-o-carboranyl-l-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)uracil (CFAU). Nucleosides and oligonucleotides bearing an -O-[(carboran-1-yl)alkyl]phosphate, S-[(carboran-1-yl)alkyl]phosphorothioate, or Se-[(carboran-1-yl)alkyl]phosphoroselenoate in place of the (carboran-1-yl)phosphonate moiety can be used. Oligonucleotides of specific gene sequences that include one or more 3', 5'-linking-(carboran-1-yl)phosphonate moieties can also be used in antisense therapy in the selective modification of gene expression. Compounds can be used in urogenital BNCT therapy that contain boron clusters as a means to enhance lipophilicity wherein the boron is not enriched in 10B, but instead, in the 11B isotope. The therapy is accomplished by administering the boron-containing compound by any appropriate route, including by intravenous injection, oral delivery or by catheter or other direct means, in such a manner that the compound accumulates in the target tumor. After desired accumulation of the compound in the tumor, the site is irradiated with an effective amount of low energy neutrons.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/334,759 US5599796A (en) | 1993-12-02 | 1994-11-04 | Treatment of urogenital cancer with boron neutron capture therapy |
US08/334,759 | 1994-11-04 | ||
PCT/US1995/014450 WO1996014073A1 (en) | 1994-11-04 | 1995-11-06 | Treatment of urogenital cancer with boron neutron capture therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2204160A1 true CA2204160A1 (en) | 1996-05-17 |
CA2204160C CA2204160C (en) | 2007-09-25 |
Family
ID=23308699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002204160A Expired - Fee Related CA2204160C (en) | 1994-11-04 | 1995-11-06 | Treatment of urogenital cancer with boron neutron capture therapy |
Country Status (6)
Country | Link |
---|---|
US (2) | US5599796A (en) |
EP (1) | EP0788364A4 (en) |
JP (1) | JPH10508603A (en) |
AU (1) | AU693618B2 (en) |
CA (1) | CA2204160C (en) |
WO (1) | WO1996014073A1 (en) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846741A (en) * | 1992-08-21 | 1998-12-08 | Immunomedics, Inc. | Boron neutron capture therapy using pre-targeting methods |
US6180766B1 (en) | 1993-12-02 | 2001-01-30 | Raymond F. Schinazi | Nucleosides and oligonucleotides containing boron clusters |
US5599796A (en) * | 1993-12-02 | 1997-02-04 | Emory University | Treatment of urogenital cancer with boron neutron capture therapy |
EP0729363B1 (en) * | 1994-06-27 | 2003-02-19 | Neutron Therapies Inc. | Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors |
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US5739313A (en) * | 1995-11-13 | 1998-04-14 | Regents Of The University Of Minnesota | Radionuclide labeling of vitamin B12 and coenzymes thereof |
US5885834A (en) * | 1996-09-30 | 1999-03-23 | Epstein; Paul M. | Antisense oligodeoxynucleotide against phosphodiesterase |
US6509320B1 (en) * | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
PT1132393E (en) * | 1996-10-16 | 2003-08-29 | Ribapharm Inc | L-RIBAVIRIN AND USES OF THE SAME |
CA2266889A1 (en) * | 1996-10-16 | 1998-04-23 | Guangyi Wang | Purine l-nucleosides, analogs and uses thereof |
SE513149C2 (en) * | 1997-12-05 | 2000-07-17 | Katarina Edwards | Drug distribution system with two-step targeting, to specific cells or tissue and to its cell nucleus |
US6036631A (en) * | 1998-03-09 | 2000-03-14 | Urologix, Inc. | Device and method for intracavitary cancer treatment |
US6211354B1 (en) * | 1998-05-06 | 2001-04-03 | Tosch Corporation | Optically active DNA probe having phosphonic diester linkage |
US6083936A (en) * | 1999-01-25 | 2000-07-04 | Sri International | Boron heterocycle steroid mimics and associated pharmaceutical compositions and methods of use |
US6017902A (en) * | 1999-02-25 | 2000-01-25 | Brookhaven Science Associates | Boron containing amino acid compounds and methods for their use |
US6806363B1 (en) * | 1999-04-16 | 2004-10-19 | Mayo Foundation For Medical Education & Research | Cobalamin conjugates useful as antitumor agents |
US6352500B1 (en) | 1999-09-13 | 2002-03-05 | Isotron, Inc. | Neutron brachytherapy device and method |
US6319189B1 (en) | 1999-09-13 | 2001-11-20 | Isotron, Inc. | Methods for treating solid tumors using neutron therapy |
JP2003531105A (en) | 1999-10-15 | 2003-10-21 | メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ | Cobalamin conjugates useful as contrast agents and therapeutics |
US7591995B2 (en) * | 1999-10-15 | 2009-09-22 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging and therapeutic agents |
US6817995B1 (en) | 2000-04-20 | 2004-11-16 | Isotron ,Inc. | Reinforced catheter connector and system |
US6497645B1 (en) | 2000-08-28 | 2002-12-24 | Isotron, Inc. | Remote afterloader |
EP1334114A2 (en) * | 2000-10-25 | 2003-08-13 | Mayo Foundation For Medical Education And Research | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
EP1435973A4 (en) * | 2001-09-28 | 2007-05-02 | Mayo Foundation | Coadministration of transport protein with conjugated cobalamin to deliver agents |
FR2840406B1 (en) * | 2002-06-03 | 2005-02-25 | Aventis Pharma Sa | METHOD OF DETERMINING CONCENTRATION PROFILES FROM INFRARED PROFILES AND HPLC DATA |
EP1636247A2 (en) * | 2003-05-02 | 2006-03-22 | Centrum mikrobiologii i wirusologii polskiej akade mii nauk | Nucleoside derivative, modified oligonucleotide, method for their synthesis and applications thereof |
CA2568952C (en) | 2004-06-18 | 2019-05-21 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
US8173797B2 (en) * | 2004-07-21 | 2012-05-08 | Cornell Research Foundation, Inc. | Therapeutic compounds derived from spider venom and their method of use |
US8535750B2 (en) * | 2005-05-17 | 2013-09-17 | Cargill, Incorporated | Granular lecithins, granular lysolecithins, process for their production and compositions containing them |
US20080050309A1 (en) * | 2006-08-25 | 2008-02-28 | Hadron Systems | Compositions of pharmaceuticals for use in low energy neutron therapy |
US8287839B2 (en) * | 2006-12-04 | 2012-10-16 | Brookhaven Science Associates, Llc | Carboranylporphyrins and uses thereof |
US8444953B2 (en) * | 2007-03-22 | 2013-05-21 | Brookhaven Science Associates, Llc | Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof |
US20080279781A1 (en) * | 2007-05-10 | 2008-11-13 | Brookhaven Science Associates, Llc | Glycosylated Carboranylporphyrins and Uses Thereof |
JP2008308440A (en) * | 2007-06-14 | 2008-12-25 | Genomidea Inc | Pharmaceutical delivery vehicle for cancer treatment, method for producing the same, and preparation using the same |
CA2699394C (en) | 2007-09-17 | 2020-03-24 | The Regents Of The University Of California | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
PL387217A1 (en) | 2009-02-06 | 2010-08-16 | Instytut Biologii Medycznej Polskiej Akademii Nauk | Borate derivatives of adenosine |
WO2012148295A1 (en) | 2011-04-28 | 2012-11-01 | Instytut Biologii Medycznej Polskiej Akademii Nauk | Antiviral drug derivative |
EP2941423B1 (en) | 2013-01-07 | 2021-06-09 | University of Southern California | Deoxyuridine triphosphatase inhibitors |
US20140271453A1 (en) | 2013-03-14 | 2014-09-18 | Abbott Laboratories | Methods for the early detection of lung cancer |
CA2935717C (en) | 2014-01-03 | 2022-06-21 | University Of Southern California | Uracil isostere and pharmaceutical compositions thereof useful as deoxyuridine triphosphatase inhibitors |
JP5924795B2 (en) | 2014-06-13 | 2016-05-25 | テンボロン オイ | Complex |
US9696878B2 (en) | 2014-07-21 | 2017-07-04 | Honeywell International Inc. | System and method for abstracting a display |
WO2017006283A1 (en) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
CA2991468A1 (en) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
WO2017006270A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
CA3006759A1 (en) | 2015-11-30 | 2017-06-08 | The Regents Of The University Of California | Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen |
RU2624509C1 (en) * | 2016-07-20 | 2017-07-04 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Method for treatment of inoperable asctic forms of ovarian cancer |
US11434301B2 (en) | 2016-11-11 | 2022-09-06 | The Regents Of The University Of California | Anti-CD46 antibodies and methods of use |
US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
WO2018098209A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
WO2018098206A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
WO2018128720A1 (en) | 2017-01-05 | 2018-07-12 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
WO2019115614A1 (en) * | 2017-12-12 | 2019-06-20 | Universität Leipzig | Peptidic melanocortin 1 receptor agonist - saccharide functionalised carbaborane conjugates |
IL297818A (en) | 2018-12-21 | 2023-01-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
JP2023537798A (en) | 2020-03-19 | 2023-09-06 | アビディティー バイオサイエンシーズ,インク. | Compositions and methods for treating facioscapulohumeral muscular dystrophy |
WO2021195469A1 (en) | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
EP4192511A1 (en) | 2020-08-07 | 2023-06-14 | Fortis Therapeutics, Inc. | Immunoconjugates targeting cd46 and methods of use thereof |
AU2022345098A1 (en) | 2021-09-16 | 2024-04-04 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4855493A (en) * | 1979-08-21 | 1989-08-08 | The United States Of America, As Represented By The Secretary Of The Army | Pharmacological active amine-carboxyboranes |
US4516535A (en) * | 1982-06-22 | 1985-05-14 | Nuclear Medicine, Inc. | Methods for neutron-capture tumor therapy |
US5328678A (en) * | 1987-11-04 | 1994-07-12 | Vestar, Inc. | Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy |
DE3803063A1 (en) * | 1988-01-29 | 1989-08-10 | Schering Ag | THIOHURINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE NEUTRON CAPTURE THERAPY OF MALIGNEN MELANOMAS |
US4855492A (en) * | 1988-05-27 | 1989-08-08 | Amoco Corporation | Process for production of aromatic polycarboxylic acids |
US5066479A (en) * | 1988-05-31 | 1991-11-19 | The Regents Of The Univ. Of California | Metallacarborane chelates |
US4959356A (en) * | 1989-05-26 | 1990-09-25 | The United States Of America As Represented By The United States Department Of Energy | Porphyrins for boron neutron capture therapy |
US5130302A (en) * | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5405598A (en) * | 1992-02-24 | 1995-04-11 | Schinazi; Raymond F. | Sensitizing agents for use in boron neutron capture therapy |
US5272250A (en) * | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
US5466679A (en) * | 1993-05-17 | 1995-11-14 | The Ohio State University Research Foundation | Carboranyl uridines and their use in boron neutron capture therapy |
US5599796A (en) * | 1993-12-02 | 1997-02-04 | Emory University | Treatment of urogenital cancer with boron neutron capture therapy |
US6180766B1 (en) * | 1993-12-02 | 2001-01-30 | Raymond F. Schinazi | Nucleosides and oligonucleotides containing boron clusters |
AU6697994A (en) * | 1994-03-25 | 1995-10-17 | Regents Of The University Of California, The | Macromolecular structures for boron neutron-capture therapy |
-
1994
- 1994-11-04 US US08/334,759 patent/US5599796A/en not_active Expired - Lifetime
-
1995
- 1995-11-06 EP EP95939803A patent/EP0788364A4/en not_active Withdrawn
- 1995-11-06 AU AU41483/96A patent/AU693618B2/en not_active Ceased
- 1995-11-06 JP JP8515485A patent/JPH10508603A/en active Pending
- 1995-11-06 CA CA002204160A patent/CA2204160C/en not_active Expired - Fee Related
- 1995-11-06 WO PCT/US1995/014450 patent/WO1996014073A1/en not_active Application Discontinuation
-
1997
- 1997-02-03 US US08/792,370 patent/US5872107A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1996014073A1 (en) | 1996-05-17 |
AU4148396A (en) | 1996-05-31 |
US5599796A (en) | 1997-02-04 |
CA2204160C (en) | 2007-09-25 |
US5872107A (en) | 1999-02-16 |
EP0788364A4 (en) | 1998-05-06 |
AU693618B2 (en) | 1998-07-02 |
JPH10508603A (en) | 1998-08-25 |
EP0788364A1 (en) | 1997-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2204160A1 (en) | Treatment of urogenital cancer with boron neutron capture therapy | |
Sweet et al. | The Possible Use of Neutron-Capturing Isotopes such as Boron in the Treatment of Neoplasms: 1. Intracranial Tumors | |
US4959356A (en) | Porphyrins for boron neutron capture therapy | |
Rosenshein et al. | Radiocolloids in the treatment of ovarian cancer | |
EP3424561B1 (en) | Boron neutron capture treating system and alpha-amino acid-like boron trifluoride compounds for use in treating tumors | |
US5466679A (en) | Carboranyl uridines and their use in boron neutron capture therapy | |
Coderre et al. | Boron neutron capture therapy of a murine melanoma | |
WO1990006776A1 (en) | Macrocyclic aminophosphonic acid complexes, their preparation, formulations and use | |
Gabel | Present status and perspectives of boron neutron capture therapy | |
JP2002524219A (en) | Neutron radiation equipment for cancer treatment | |
CN107224675B (en) | Boron neutron capture therapy system | |
Goldstein et al. | Biological effects of accelerated heavy ions. II. Fractionated irradiation of intestinal crypt cells | |
Akine et al. | Suppression of Rabbit VX‐2 Subcutaneous Tumor Growth by Gadolinium Neutron Capture Therapy | |
Ünak et al. | Synkavit and its direct labelling with iodine-125, as a potential anti-cancer drug | |
Pinelli et al. | Development of a method to use boron neutron capture therapy for diffused tumours of liver (TAORMINA project) | |
Smith et al. | Fast neutron irradiation for locally advanced pancreatic cancer | |
Ono et al. | The combined effect of electroporation and borocaptate in boron neutron capture therapy for murine solid tumors | |
Buchholz et al. | Boron neutron capture enhanced fast neutron radiotherapy for malignant gliomas and other tumors | |
Jonsson et al. | Nicotinamide as a radiosensitizer of a C3H mouse mammary adenocarcinoma | |
Viaggi et al. | Boron neutron capture therapy for undifferentiated thyroid carcinoma: preliminary results with the combined use of BPA and BOPP | |
Spielvogel | Boron analogues of biomolecules: biomedical prospects | |
Masunaga et al. | Applicability of the 2-nitroimidazole-sodium borocaptate-10B conjugate, TX-2060, as a 10B-carrier in boron neutron capture therapy | |
Brugger et al. | Intermediate energy neutron beams from the MURR | |
WO1989000062A1 (en) | Radiotherapy | |
Coderre et al. | Neutron capture therapy for melanoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |